SCHEMBL1085045

SCHEMBL1085045

COc1cc(-c2cccc(C(F)(F)F)c2)cc(C)c1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.47
▸ GAA P10253 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ AKR1C3 P42330 1/20 0.43
▸ AKR1C2 P52895 1/20 0.43
▸ RORB Q92753 3/20 0.40
▸ RORC P51449 1/20 0.40
▸ PDE4B Q07343 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CACNA1G O43497 1/20 0.40
▸ CACNA1B Q00975 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40
▸ MMP1 P03956 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085401 0.83 NPSR1 (0.47) NPSR1GAAHPGDSMN1; SMN2KDM4E
SCHEMBL1085143 0.79 AKR1C3 (0.50) NPSR1GAAHPGDSMN1; SMN2KDM4E
SCHEMBL30743622 0.78 ABCG2 (0.37) GAAAKR1C3AKR1C2RORCL3MBTL1
SCHEMBL22654828 0.78 ABCG2 (0.37) GAAAKR1C3AKR1C2RORCL3MBTL1
SCHEMBL16290810 0.76 AKR1C3 (0.47) NPSR1GAAHPGDSMN1; SMN2KDM4E
SCHEMBL30084323 0.73 AKR1C3 (0.42) NPSR1GAAHPGDSMN1; SMN2KDM4E
SCHEMBL14499450 0.72 RXRA (0.54) NPSR1GAAKDM4EAKR1C3AKR1C2
SCHEMBL29678302 0.72 TSHR (0.58) ALDH1A1
SCHEMBL1263144 0.72 TSHR (0.58) ALDH1A1
SCHEMBL16068235 0.72 NPSR1 (0.57) NPSR1HPGDSMN1; SMN2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 — — US disclosed
EP-2205583-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-07-14 — — EP disclosed
WO-2009043747-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-09 — — WO disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 NPSR1 283/4885GAA 3909/4885HPGD 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback